{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:57:36Z","timestamp":1790852256413,"version":"4.1.0"},"reference-count":2,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jdin.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:48:24Z","timestamp":1785221304000},"page":"95-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers \u2013 by Provider and Drug dataset"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2924-1189","authenticated-orcid":false,"given":"Nathan C.","family":"Schedler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manaal","family":"Saqib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenan A.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdin.2026.07.006_bib1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2024.04.030","article-title":"Dermatology medications with the highest cost burden on Medicare Part D: potential implications of the Inflation Reduction Act","volume":"91","author":"Chen","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2026.07.006_bib2","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaad.2025.02.059","article-title":"Biosimilar pricing, adoption, and hurdles: early lessons from adalimumab","volume":"92","author":"Lin","year":"2025","journal-title":"J Am Acad Dermatol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328726001367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328726001367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:15:15Z","timestamp":1790849715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328726001367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":2,"alternative-id":["S2666328726001367"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2026.07.006","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers \u2013 by Provider and Drug dataset","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}